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Abstract 
Background/Objectives: To determine whether general dietary supplement use is associated 
with cancer risks in UK women; to estimate risks relating to use at one and at two recording 
points. 
Subject/Methods: Cox’s proportional hazard regression models were used to estimate cancer 
risks for 32 665 middle-aged women in the UK Women’s Cohort Study (UKWCS) relating to any 
current supplement use recorded by baseline questionnaire. During a median follow-up of 15 
years there were 3 936 registered cancer incidences, including 1 344 breast, 429 smoking-
related and 362 colorectal cancers. Cancer risks for 12 948 of these women, who also 
completed questionnaires on average 4.4 years later, were estimated in relation to any 
supplement use at both time points (1 527 cancers, including 561 breast, 131 smoking-related 
and 141 colorectal cancers). Adjustments were made for baseline confounders.  
Results: Total smoking-related cancers were associated with baseline supplement use 
(HR=1.41; 95% CI: 1.10, 1.81) compared to non-use, but not associated with use at both 
recording points (HR=1.29; 95% CI: 0.78, 2.13) compared to use at neither. There was no 
evidence of associations between total, colorectal or breast cancers and baseline supplement 
use, or use at both recording points. In sub-analyses, no significant associations with breast 
cancer were found for pre-menopausal or post-menopausal baseline users, or similarly for use 
at both points (HR=1.35; 95% CI: 0.91, 2.01 and HR=0.93; 95% CI: 0.68, 1.26 respectively).   
Conclusion:  There was evidence that general supplement use was associated with increased 
smoking-related cancer risk, but no evidence of associations with total, colorectal and breast 
cancers. 
Key Words: Dietary supplements, Cohort studies, cancer, breast cancer 
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Introduction 
A large proportion of UK women take supplements; 41% of women in the 2008/9 National Diet 
and Nutrition Survey reported using supplements in the previous year.1 Some women may take 
supplements to reduce their risk of chronic diseases.2 However, the 2007 World Cancer 
Research Fund (WCRF) review clearly states that supplements are not recommended for 
cancer prevention, and reports no convincing evidence from their systematic reviews that 
specific micronutrients in supplement form protect against the risk of developing cancers that 
affect women.3 Furthermore, increased lung cancer risks were found for smokers who used 
high-dose β-carotene supplements.4, 5 
 
Supplementation with a variety of micronutrients may not be protective either; a meta-analysis 
of Randomised Control Trials (RCTs) showed no association between multivitamin supplement 
use and cancer mortality.6 Nevertheless, multivitamin use has recently been reported to reduce 
total cancer risk in men in a large US RCT;7 men, though, tend to have lower baseline 
antioxidant status than women indicative of a poorer diet.8 Two large US cohort studies reported 
no association between multivitamin supplement use in women and total cancer incidence, or 
cancer at the major sites such as breast, colorectal and lung.9, 10 Ten year, long-term use of 
multivitamins, which contain low-dose micronutrients, was also not associated with lung cancer 
in the Vitamins and Lifestyle (VITAL) cohort study.11 High-dose users tend to take a number of 
supplement types,12 and therefore are likely to supplement with a range of micronutrients. 
However, the majority of previous research has analysed risks relating to single supplements 
rather than multiple or general supplement use.  
 
Although RCTs are less prone to bias than observational studies, supplementation over the 
intervention period may be insufficient to affect long-term risks, and these periods are usually 
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substantially shorter than follow-up periods in most prospective observational studies. 
Additionally, unlike drug trials, members of control groups can easily obtain supplements. On 
the other hand, it is possible that the sporadic nature of supplement use in free-living 
populations, as highlighted in European Prospective Investigation into Cancer (EPIC)-
Heidelberg,13 might explain lack of associations or inconsistencies in results in cohort studies. 
However, only the analyses of the EPIC-Heidelberg cohort  and a Japanese cohort study have 
assessed whether general supplement use at more than one recording point was associated 
with cancer incidence,14 or with cancer mortality,15 and no associations were found for users 
who took supplements at more than one recording point.  However, there was evidence from 
these cohorts that users at more than one recording point had a healthier diet compared to past 
and new users as well as non-users.13, 14  
 
This study prospectively analyses the relationship between current use of any supplement type 
and total cancers, smoking-related cancers,16, 17 colorectal and breast cancer risk in UK women. 
In secondary analyses the cancer risks for women using supplements at two recording points, 
and the risks for use at only one of these points, are compared with the risks for women not 
taking supplements at either point. Additionally, characteristics of UK women in these different 
supplement user groups are compared. 
 
Materials and Methods 
Study population 
UKWCS recruitment data was gathered between1995-1998 from 35 367 women aged between 
33 and 74 years old who completed a 217-item validated food frequency questionnaire (FFQ).18 
19, 20 This national cohort of mainly Caucasian, well-educated, middle-class, middle-aged, 
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married women was designed to compare disease incidence in vegetarians, fish-eaters and 
meat-eaters.18 At recruitment 34 958 (99%) provided information about whether or not they took 
supplements.   
Women with any prevalent malignant cancers recorded in UK cancer registries before baseline 
cohort entry were excluded. This provided 32 665 women for the risk analysis which compared 
women who took supplements at baseline with those that did not. Over the median follow-up 
period of 15 years there were 3 936 malignant cancer incidences (including non-melanoma skin 
cancers) ascertained from UK cancer registries via the UK Office of National statistics (ONS). 
These included 1 344 breast and 362 colorectal cancers diagnosed by the censor date 
01/10/2011. There were also 429 smoking-related cancers16, 17 (lung (172), cervical (27), 
bladder (53), kidney (48), oesophageal (47), stomach (24) and pancreas (66)). 
To explore the stability of general supplement use between two survey points, further secondary 
analyses were undertaken for 12 948 of the above women who also completed supplement 
questions on the UKWCS second survey between two and five years after baseline (4.4 years 
on average). These women were split into three categories. ’Users at both’ were defined in 
these analyses as women who were taking any type of supplement at both the baseline and the 
second survey. ‘New/past users’ reported taking supplements at only one of the two survey time 
points and ‘never-users’ reported no supplement use at either. Over a median follow-up of 15 
years from baseline there were 1 527 incident cancers in total and 561 incident breast,  131 
smoking-related and 141 colorectal cancers registered to censor date 01/10/2011 in these 12 
948 women. One hundred and forty eight (26%) of the 561 breast cancer cases and 308 (20%) 
of the 1 527 total cancer cases occurred between baseline and the second survey in the 
UKWCS.  
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Data collection  
General supplement use at baseline was determined by questionnaire using self-reported 
yes/no answers to: 
Do you take any vitamins, minerals, fish oils or other food supplements? 
General supplement use at the second survey was determined by questionnaire using self-
reported yes/no answers to: 
Do you presently use any dietary supplements? 
Supplements were defined on this second survey questionnaire as vitamins, minerals, fibre, fish 
oils or other food supplements. Additionally, if participants did not answer yes to the above 
questions but provided details of any type of supplements taken, regardless of amount taken, 
then these women were designated as being general supplement users. The most popular 
supplement types taken daily were determined at this second survey where women were asked 
to indicate the frequency of types they took from a list of 16 types provided on the questionnaire.  
 
Covariates were derived from the health and lifestyle part of the baseline questionnaire except 
for total alcohol intake and total energy intake which were derived from the baseline FFQ. 
Statistical analyses 
Characteristics of women in the different supplement use categories were described using 
means and percentages. Significant differences between means of baseline users and non-
users were established using t-tests and significant differences between categories were 
established using chi squared tests. Any significant trends across groups from ‘never-users’ to 
‘new/past users’ to ‘users at both’ were determined using linear regression followed by tests for 
linear hypotheses for means, or using chi squared tests for trend for dichotomous variable 
percentages.  
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Cox proportional hazards regression was used to provide hazard ratios to estimate cancer risks 
in relation to supplement use for women in the UKWCS. The reference group in the main 
analyses were ‘non-users’ at baseline, whereas in the secondary analyses cancer risks for 
‘users at both’ and ‘new/past users’ categories were compared to ‘never-users’. Probability 
weighting was used to produce estimated average risks representative of the UK population of 
women: needed because of the recruitment of substantially higher proportions of vegetarians 
and fish eaters into the cohort compared to the UK population. Vegetarians and fish eaters were 
weighted by 0.27 and 0.43 respectively. Adjustments were made in the total cancers, smoking-
related cancers and colorectal cancer analyses for age; BMI (underweight, normal, overweight, 
obese); education (none, up to degree level, degree); smoking status (never, past, current 
occasionally, current every day), minutes sweating exercise per week; alcohol intake (g/day); 
total energy intake (kcal/d) and dietary type (mainly meat, oily fish, other fish eater, vegetarian 
as described elsewhere18). In addition to the above, the breast cancer analyses were adjusted 
for contraceptive pill use (never, past, current); Hormone Replacement Therapy (HRT) (never, 
past, current); age at menarche, and parity, but not smoking status. Although there was no 
interaction between supplement use at baseline and menopausal status in relation to breast 
cancer risks in likelihood ratio tests for interactions, hazard ratios were examined by 
menopausal status, as commonly practised in breast cancer risk analyses. Menopausal status 
at baseline was determined from responses to a number of questions relating to last natural 
period, HRT and contraceptive pill use, hysterectomy and ovary removal.21 Sensitivity analyses 
were undertaken to make additional adjustments for family history of cancer in first degree 
relatives (missing data was >5%) and in the breast cancer analysis for estimated weeks of 
breastfeeding. Other sensitivity analyses excluded incident cancers within two years of baseline. 
Further sensitivity analysis, with a median follow-up time of 10.6 years, was undertaken relating 
to use at two time points where the time-to-event calculation was started from the second 
survey date instead of from baseline, thereby excluding incident cases diagnosed between the 
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surveys. Analyses were carried out using Stata version 12 (Timberlake Consultants UK, 
London, UK) and results were based on a significance level of P<0.05. 
 
Results 
Of the 32 665 eligible women, 62% were supplement users at baseline and 54% of the 12 948 
women at the second survey had taken supplements at both recording points, and were classed 
as users at both. At the second survey 25% were new/past users (had taken supplements at 
either recording point but not at both) and 21% were never-users. Of the 8 915 (69%) women 
who were currently taking supplements at the second survey, 7010 (79%) had also taken 
supplements at baseline and were classed as users at both. On the second survey 
questionnaire 27% of all women reported taking fish oils, 25% multivitamins/minerals, 19% 
primrose/starflower oil, 18% vitamin C and 14% calcium supplements on a daily basis. These 
were the most popular named supplement types, and for each of these there were statistically 
significant differences in intake between menopausal statuses: multivitamins and 
primrose/starflower oil were more likely to be used by pre-menopausal women, whereas cod 
liver oil and the others were more likely to be taken by women of post-menopausal age.  
There were statistically significant differences between general supplement users and non-
users at baseline for the majority of characteristics listed in table 1. In particular, users reported 
a higher fruit and vegetable intake, a lower meat intake, lower alcohol intake and reported doing 
more vigorous exercise than non-users. Users were also more likely to have a family history of 
any cancer. However, there were no significant differences in level of education.  
Similarly as observed in table 2, there were increasingly healthier behaviours relating to 
exercise, alcohol use and fruit and vegetable intake, meat intake from never-users (at baseline 
and second survey), through new/past users, to users at both. There was a decreasing trend for 
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HRT use, number of children and estimated cumulative breast feeding, but an increase in trend 
for supplement use for ex-smokers. However, there were no significant differences between 
user frequency in relation to family history of cancer. 
As observed in table 3 in the analysis of supplement use assessed at baseline for all women 
there was no statistically significant difference in total cancers, colorectal or breast cancer risk 
between all supplement users and non-users either in the unadjusted or adjusted analyses 
(adjusted HR=1.06; 95% CI: 0.98, 1.14, HR=1.13; 95% CI: 0.87, 1.46 and HR=1.01; 95% CI: 
0.89, 1.15 respectively). There was no evidence of interactions between supplement use and 
menopausal status (p=0.13) or HRT use on breast cancer risk. Furthermore in the sub-analysis 
by menopausal status, hazard ratios were not statistically significant: (adjusted HR=0.96; 95% 
CI: 0.81, 1.13 and HR=1.07; 95% CI: 0.88, 1.30 for post-menopausal women and pre-
menopausal respectively as shown in table 3). However, an association was found for smoking-
related cancers (HR=1.41; 95% CI: 1.10, 1.81, p=0.007) which remained after excluding 
cancers occurring within 2 years of the baseline (HR=1.36; 95% CI: 1.05, 1.76, p=0.02).  
 
Similarly in the secondary analysis exploring consistency of supplement-taking between 
baseline and the second survey, compared to never-users there was no significant differences 
in risks of total cancers, colorectal and breast cancer in the adjusted analyses for new/past 
users (HR=0.96; 95% CI: 0.81; 1.14, HR=0.71; 95% CI: 0.40, 1.26; and HR=0.98; 95% CI: 0.73, 
1.30 respectively), and users at both (HR=1.01; 95% CI: 0.88, 1.17; HR=1.00; 95% CI: 0.63; 
and HR=1.08; 95% CI: 0.85, 1.38 respectively) as observed in table 4. Although the point 
estimates were raised in the pre-menopausal sub-analysis they were not statistically significant 
(HR=1.17; 95% CI: 0.74, 1.84 and HR=1.35; 95% CI: 0.91, 2.01 respectively for past/new users 
and users at both). Additionally, no evidence of associations was found for smoking-related 
cancers for past/new users (HR=0.97 95%CI: 0.53, 1.79) or for users at both (HR=1.29; 95% CI: 
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0.78, 2.13). Additional adjustment for estimated cumulative breast feeding duration in the breast 
cancer analyses and for family history of cancer had little effect on hazard ratios and confidence 
intervals in the above analyses.  
 
The results of the sensitivity analysis which excluded cases diagnosed within two years of 
baseline or diagnosed between supplement-taking surveys did not affect the overall conclusion 
of this research (data not shown).    
 
Discussion   
There was little evidence of associations between general supplement use and total cancers, 
colorectal and breast cancer risk in this UK cohort, whether comparing risks for supplement 
users at one recording point with non-users or comparing risk for users at two recording points 
with never-users or comparing past/new users with never users. There was evidence that 
general supplement use was associated with increased smoking-related cancer risk in the full 
sample baseline analysis. However, this was not significant for the users at both recording 
points, but this secondary analysis was limited by lower numbers and therefore lower power. 
There was evidence, however, that users at both recording points had different characteristics 
from women who had not used supplements at one or both points.  
Descriptive results from these UKWCS analyses support the inverse supplement hypothesis 
that supplement users lead a healthier lifestyle than non-users, as found in the UK,22-24 and 
elsewhere.25-30 In particular, supplement users in the UKWCS had on average a higher intake of 
fruit and vegetables, a lower intake of meat and alcohol, and also spent more time exercising 
vigorously, and had lower BMIs. Moreover, the results show a trend towards these healthier 
behaviours from never-users, new/past users to users at both. Similarly, women taking 
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supplements at all three recording points in the EPIC-Heidelberg cohort in Germany, classed as 
‘consistent users’, had the highest intake of dairy products, fish, fruit and vegetables and wine, 
the highest physical activity but the lowest intake of meat compared to the other categories, 
producing trends for all but physical activity.13 In the cohort of Japanese women, ‘consistent 
users’ had lower BMIs and consumed significantly larger amounts of fruits, folate and vitamin C 
than the other categories, but were more likely to be regular alcohol drinkers and exercised less, 
additionally there were no significant trends for green vegetables, meat and fish intake.14 In 
these previous studies, unlike the current study, ex-smokers were more likely to be inconsistent 
users. Trends in HRT or contraceptive pill use were found in the current study, but were not 
examined in the previous studies.  
 
The increased risk in smoking-related cancers in the baseline analysis, found after adjustment 
for confounders, may relate to evidence that high-dose β-carotene is associated with increased 
lung 4, 5 and other smoking-related cancer risks in smokers.31 Conversely, β-carotene has also 
been inversely associated with smoking-related cancer risks in non-smokers.31 Potentially, β-
carotene may act as a pro-oxidant or antioxidant depending upon the biological environment.32 
Unfortunately, the amount of β-carotene taken in supplements by the UKWCS users in the 
current analyses was not reported by questionnaire and is unknown, though is usually present 
in low doses in popular multivitamin supplements.33 Furthermore, since only 11% of the women 
smoked, numbers were considered too low to power sub-analyses by smoking status in relation 
to general supplement use. Alternatively, the increased risks found in the main analysis may be 
due to other micronutrients in supplements, confounding or multiple testing. The lack of 
association for smoking-related cancers for users at the two recording points in the UKWCS 
does not support the main analysis finding; this may be due, however, to fewer cases and 
shorter follow-up time from use at the second survey in this secondary analysis.  
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There was no evidence of significant associations between general supplement use at baseline 
and later incidences of total cancers, colorectal or breast cancer for all women, or when 
explored by menopausal status in the breast cancer analysis. This is in line with results from a 
breast cancer meta-analysis,34 and also results from two large cohort studies which reported no 
associations between multivitamin use in women and total cancers, colorectal or breast cancer, 
as well as lung cancer incidence.9, 10 There is some prior evidence, however, that folic acid in 
multivitamins is associated with reduced risk of early stages of colorectal cancer.35 The breast 
cancer results support those from two Danish and US case–control studies on general 
supplement use;36, 37 however, they are in contrast to a Taiwanese case–control study where 
general supplement use was associated with a reduced risk of breast cancer (OR=0.40, 95% 
CI: 0.3, 0.7).38 Selection and recall bias, which can occur in case-control studies, possible lower 
dietary intakes of micronutrients in the Taiwanese women or the nature of the supplements 
taken could account for discrepancies in results.  
 
Additionally, there were no associations between reporting supplement use at two recording 
points (both baseline and second survey) and total cancers, colorectal or breast cancer risk for 
all women, and by menopausal status in the breast cancer analysis. The current study is the 
first to analyse cancer risks for UK women reporting supplement use at more than one time 
point in comparison to never-users. Previously, only two studies had analysed general 
supplement use at more than one recording point in relation to cancer, reporting no associations 
for ‘consistent users’  in relation to total cancer and major site-specific cancers in a Japanese 
cohort incidence, and total mortality in the German EPIC-Heidelberg cohort.14, 15   
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Major strengths of the UKWCS study are the prospective design and the large number of cancer 
cases, particularly in the baseline analysis. However, the power to detect associations was 
substantially reduced in the analysis of users at two recording points, though numbers in this 
category were larger (7 010 (54%)) compared with previous studies (German men and women: 
3 559 (18%) ; Japanese women: 1962 (5.8%)),14, 15. Another limitation of this secondary analysis 
in the UKWCS is that within the category of ‘users at both’ it was not possible to distinguish 
between regular users who took any supplements several days each week and sporadic users. 
Misclassification of sporadic users in the UKWCS into this ‘users at both’ category for pre-
menopausal women, for instance, would have attenuated risks in this category, if cancer risk 
were lower for sporadic users. However, the questions relating to regular intake, used to define 
consistent use in the two previous studies, 14, 15 indicate the women in this group in those studies 
were more likely to be stable longer-term users. The average period between baseline and final 
supplement use recordings was also shorter in the UKWCS. A limitation in the current and 
previous studies is that it was unknown whether the same types of supplements were taken at 
baseline as those at follow-up surveys: it was unknown for how long, how frequently, how many 
and at what doses supplements were taken.  
Although supplement use in nutrient deficient populations may be required to reduce the 
development of cancer,39 any protective effects of general supplement use per se on cancer risk 
in well-nourished populations such as the UKWCS would be more difficult to explain biologically.  
As previously reported, many of the UKWCS took a variety of supplement types.12 In line with 
findings from a small 2008 UK national survey,40 at the UKWCS second survey cod liver oil was 
more likely to be taken by women of post-menopausal age, whereas multivitamins were more 
likely to be used by younger women. Whether or not these supplement types have different 
associations with breast cancer risk, differences in estimates between menopausal statuses in 
the current analyses were not significant, neither were the increased risk estimates across use 
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categories for pre-menopausal women significant. Further research is needed into pre-
menopausal users, particularly with larger sample sizes, as research is lacking in this area. 
While observational data such as these are only able to highlight links between diet and disease 
incidence rather than provide causal evidence, the apparent lack of benefit associated with 
general supplement use on cancer risks shown in this UK cohort lends support to the guidelines 
produced by the World Cancer Research Fund that supplement-taking is not advised for 
reducing cancer risk. 
 
Acknowledgement 
The UK Women’s Cohort Study was conceived and designed by JEC and the creation was 
funded by the World Cancer Research Fund. JH conducted the analysis for this manuscript, 
wrote the first version and contributed to all other versions. DCG provided statistical advice. All 
authors contributed to the design of the analysis and the write-up.  
 
There is no conflict of interest to disclose. 
15 
 
References 
1. Bates B, Lennox A, Swan G. The National Diet & Nutrition Survey: Headline results from 
Year 1 of the Rolling Programme (2008/2009). FSA: London, 2009. 
 
2. Neuhouser ML, Patterson RE, Levy L. Motivations for Using Vitamin and Mineral 
Supplements. Journal of the American Dietetic Association 1999; 99(7): 851-854. 
 
3. WCRF/AICR. Food, nutrition, physical activity, and the prevention of cancer: a global 
perspective,  AICR: Washington, DC, 2007. 
 
4. Albanes D, Heinonen OP, Taylor PR, Virtamo J, Edwards BK, Rautalahti M et al. Alpha-
tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-
tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics 
and study compliance. J Natl Cancer Inst 1996; 88(21): 1560-1570. 
 
5. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A et al. Effects of a 
Combination of Beta Carotene and Vitamin A on Lung Cancer and Cardiovascular 
Disease. New England Journal of Medicine 1996; 334(18): 1150-1155. 
 
6. Macpherson H, Pipingas A, Pase MP. Multivitamin-multimineral supplementation and 
mortality: a meta-analysis of randomized controlled trials. The American Journal of 
Clinical Nutrition 2013; 97(2): 437-444. 
 
7. Gaziano JM, Sesso HD, Christen WG, Bubes V, Smith JP, MacFadyen J et al. Multivitamins 
in the prevention of cancer in men: The Physicians' Health Study II randomized 
controlled trial. JAMA 2012; 308(18): 1871-1880. 
 
8. Hercberg S, Czernichow S, Galan P. Antioxidant vitamins and minerals in prevention of 
cancers: lessons from the SU.VI.MAX study. Br J Nutr 2006; (96): S28-S30. 
 
9. Neuhouser ML, Wassertheil-Smoller S, Thomson C, Aragaki A, Anderson GL, Manson JE et 
al. Multivitamin use and risk of cancer and cardiovascular disease in the Women's 
Health Initiative Cohorts. Arch Intern Med 2009; 169(3): 294-304. 
 
10. Park S-Y, Murphy SP, Wilkens LR, Henderson BE, Kolonel LN. Multivitamin use and the 
risk of mortality and cancer incidence. Am J Epidemiol 2011; 173: 906-914. 
 
11. Slatore CG, Littman AJ, Au DH, Satia JA, White E. Long-Term Use of Supplemental 
Multivitamins, Vitamin C, Vitamin E, and Folate Does Not Reduce the Risk of Lung 
Cancer. American Journal of Respiratory and Critical Care Medicine 2008; 177(5): 524-
530. 
 
12. Hutchinson J, Burley VJ, Greenwood DC, Thomas JD, Cade JE. High-dose vitamin C 
supplement use is associated with self-reported histories of breast cancer and other 
illnesses in the UK Women’s Cohort Study. Public Health Nutr. 2011; 14(05 ): 768-777. 
 
16 
 
13. Li K, Kaaks R, Linseisen J, Rohrmann S. Consistency of vitamin and/or mineral supplement 
use and demographic, lifestyle and heath-status predictors: findings from the European 
Prospective Investigation into Cancer and Nutrition (EPIC)-Heidelberg cohort. Br J Nutr 
2010; 104(7): 1058-1064. 
 
14. Hara A, Sasazuki S, Inoue M, Shimazu T, Iwasaki M, Sawada N et al. Use of vitamin 
supplements and risk of total cancer and cardiovascular disease among the Japanese 
general population: A population-based survey. BMC Public Health 2011; 11: 540. 
 
15. Li K, Kaaks R, Linseisen J, Rohrmann S. Vitamin/mineral supplementation and cancer, 
cardiovascular, and all-cause mortality in a German prospective cohort (EPIC-
Heidelberg). Eur J Nutr 2011; 51: 407-413. 
 
16. Batty GD, Kivimaki M, Gray L, Davey Smith G, Marmot MG, Shipley MJ. Cigarette smoking 
and site-specific cancer mortality: testing uncertain associations using extended follow-
up of the original Whitehall study. Annals of Oncology 2008; 19(5): 996-1002. 
 
17. Vineis P, Alavanja M, Buffler P, Fontham E, Franceschi S, Gao YT et al. Tobacco and 
Cancer: Recent Epidemiological Evidence. Journal of the National Cancer Institute 2004; 
96(2): 99-106. 
 
18. Cade JE, Burley VJ, Greenwood DC, The UKWCS Steering Group. The UK Women's 
Cohort Study: comparison of vegetarians, fish-eaters and meat-eaters. Public Health 
Nutr. 2004; 7(07): 871-878. 
 
19. Cade JE, Burley VJ, Greenwood DC, The UKWCS Steering Group. Dietary fibre and risk of 
breast cancer in the UK Women's Cohort Study. Int J Epidemiol 2007; 36(2): 431-438. 
 
20. Taylor EF, Burley VJ, Greenwood DC, Cade JE. Meat consumption and risk of breast 
cancer in the UK Women's Cohort Study. Br J Cancer 2007; 96(7): 1139-1146. 
 
21. Cade JE, Burley VJ, Greenwood DC. Dietary fibre and risk of breast cancer in the UK 
Women's Cohort Study. International Journal of Epidemiology 2007; 36(2): 431-438. 
 
22. Harrison RA, Holt D, Pattison DJ, Elton PJ. Are those in need taking dietary supplements? 
A survey of 21,923 adults. Br J Nutr 2004; 91(04): 617-623. 
 
23. Kirk SFL, Cade JE, Barrett JH, Conner M. Diet and lifestyle characteristics associated with 
dietary supplement use in women. Public Health Nutr. 1999; 2(01): 69-73. 
 
24. McNaughton SA, Mishra GD, Paul AA, Prynne CJ, Wadsworth MEJ. Supplement use is 
associated with health status and health-related behaviors in the 1946 British birth 
cohort. J Nutr 2005; 135(7): 1782-1789. 
 
25. Brownie S. Characteristics of older dietary supplement users: review of the literature. 
Australas J Ageing 2005; 24(2): 77-87. 
17 
 
 
26. Frank E, Bendich A, Denniston M. Use of vitamin-mineral supplements by female 
physicians in the United States. Am J Clin Nutr 2000; 72(4): 969-975. 
 
27. Lyle BJ, Mares-Perlman JA, Klein BEK, Klein R, Greger JL. Supplement users differ from 
nonusers in demographic, lifestyle, dietary and health characteristics. J Nutr 1998; 
128(12): 2355-2362. 
 
28. Patterson RE, Neuhouser ML, White E, Hunt JR, Kristal AR. Cancer-related behavior of 
vitamin supplement users. Cancer Epidemiol Biomarkers Prev 1998; 7(1): 79-81. 
 
29. Reinert A, Rohrmann S, Becker N, Linseisen J. Lifestyle and diet in people using dietary 
supplements. A German cohort study. Eur J Nutr 2007; 46(3): 165-173. 
 
30. Shikany JM, Patterson RE, Agurs-Collins T, Anderson G. Antioxidant supplement use in 
Women's Health Initiative participants. Prev Med 2003; 36(3): 379-387. 
 
31. Touvier M, Kesse E, Clavel-Chapelon F, Boutron-Ruault M-C. Dual Association of β-
Carotene With Risk of Tobacco-Related Cancers in a Cohort of French Women. Journal 
of the National Cancer Institute 2005; 97(18): 1338-1344. 
 
32. Palozza P, Serini S, Trombino S, Lauriola L, Ranelletti FO, Calviello G. Dual role of β-
carotene in combination with cigarette smoke aqueous extract on the formation of 
mutagenic lipid peroxidation products in lung membranes: dependence on pO2. 
Carcinogenesis 2006; 27(12): 2383-2391. 
 
33. Tanvetyanon T, Bepler G. Beta-carotene in multivitamins and the possible risk of lung 
cancer among smokers versus former smokers. Cancer 2008; 113(1): 150-157. 
 
34. Chan ALF, Leung HWC, Wang SF. Multivitamin supplement use and risk of breast cancer: 
a meta-analysis. Ann. Pharmacother. 2011; 45(4): 476-484. 
 
35. Lee JE, Willett WC, Fuchs CS, Smith-Warner SA, Wu K, Ma J et al. Folate intake and risk 
of colorectal cancer and adenoma: modification by time. Am J Clin Nutr 2011; 93(4): 
817-825. 
 
36. Ewertz M, Gill C. Dietary factors and breast cancer risk in Denmark. Int J Cancer 1990; 
46(5): 779-784. 
 
37. Moorman PG, Ricciuti MF, Millikan RC, Newman B. Vitamin supplement use and breast 
cancer in a North Carolina population. Public Health Nutr. 2001; 4(3): 821-827. 
 
38. Lee MM, Chang IYH, Horng CF, Chang JS, Cheng SH, Huang A. Breast cancer and dietary 
factors in Taiwanese women. Cancer Causes Control 2005; 16(8): 929-937. 
 
18 
 
39. Qiao Y-L, Dawsey SM, Kamangar F, Fan J-H, Abnet CC, Sun X-D et al. Total and cancer 
mortality after supplementation with vitamins and minerals: follow-up of the Linxian 
General Population Nutrition Intervention Trial. J Natl Cancer Inst 2009; 101(7): 507-
518. 
 
40. GfK Social Research. Consumer consumption of vitamin and mineral food supplements: 
Random Location Omnibus Survey 2008. In, 2009. 
 
  
19 
 
Table 1 Characteristics of all supplement users and non-users at baseline in the UKWCS 
 Non-users 
N=12495  
(38%) 
Users 
N=20170  
(62%) 
Difference in 
mean 
(95% CI) 
 
p 
Age  (years) mean (sd)  51.6 (9) 52.4 (9) -0.78 (-0.99,-0.57) <0.001 
Weight (kg) mean (sd) 66.6 (12) 65.0 (12)  1.57 ( 1.30, 1.84) <0.001 
BMI (kg/m
2
) mean (sd) 24.8 (4) 24.2 (4)  0.63 ( 0.53, 0.73) <0.001 
Age at menarche (years) 12.8 (2) 12.8 (2) -0.04 (-0.07, 0.00)   0.04 
Parity mean (sd) 1.92 (1.3) 1.82 (1.3)  0.09 ( 0.06, 0.12) <0.001 
Est cumulative breast feeding (weeks) 25.1 (37) 22.8 (34)  2.28 ( 1.49, 3.06) <0.001 
Vigorous exercise (mins/d) mean (sd) 14.0 (28) 15.9 (30) -1.86 (-2.53,-1.20) <0.001 
Total energy intake (kcal/d) mean (sd) 2338 (827) 2373 (767)  -34.8 (-52.4,-17.1 <0.001 
Alcohol intake (g/day) mean (sd) 9.0 (11)  8.5 (10)   0.50 (0.27, 0.73) <0.001 
Total meat intake (g/day) mean (sd) 73.6 (69.1)  60.1 (64.1)  13.5 (12.0, 14.9) <0.001 
Total fruit & veg (g/day) mean (sd) 596 (364) 656 (369) -60.4 (-68.6,-52.2) <0.001 
     
Dietary type n (%)    <0.001 
Mainly Meat eater  9311 (74.5) 13429 (66.6)   
Oily Fish eater  198 (1.6) 603 (3.0)   
Other fish eater  916 (7.3) 2135 (10.6)   
Vegetarian   2070 (16.6) 4003 (19.9)   
Never smoked n(%) 7116 (58.5) 11288 (57.7)    0.2 
Ex-smoker n(%) 3540 (29.1) 6211 (31.8)  <0.001 
Never used HRT n(%) 8527 (70.1) 13079 (66.5)  <0.001 
Never used pill n(%) 3884 (31.5) 6458 (32.8)    0.01 
Socio-economic status n(%)      0.8 
Higher 4807 (39.1) 7743 (39.0)   
Middle 5201 (42.4) 8463 (42.7)      
Lower 2276 (18.5) 3621 (18.3)   
Education level n(%)       0.1 
No qualifications 2110 (16.9) 3395 (16.8)   
Non-degree qualifications 7151 (57.2) 11759 (58.3)   
Degree 3234 (25.9) 5016 (24.9)      
Family history of any cancer n(%) 4491 (38.2) 7546 (39.8)   0.007 
Family history of breast cancer n(%) 872 (7.4) 1459 (7.7)     0.4 
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Table 2 Baseline characteristics of women in the UKWCS according to supplement use at 
baseline and second survey for never users; past/new users and users at both 
 Never
1
 
users 
Past/new
2
 
users 
Users at 
both
3
 
N=7010  
(54%) 
P value 
for trend  N=2765  
(21%) 
N=3173  
(25%) 
Age  (years) mean (sd)  52.1 (9) 51.2 (9) 52.6 (9) <0.001 
Weight (kg) mean  (sd) 65.4 (12) 65.4 (12) 64.0 (11) <0.001 
BMI (kg/m
2
) mean (sd) 24.5 (4) 24.4 (5) 23.9 (4) <0.001 
Age at menarche (years) mean (sd) 12.8 (2) 12.8 (2) 12.8 (2)   0.2 
Parity mean (sd) 1.92 (1.3) 1.86 (1.3) 1.82 (1.3)   0.004 
Cumulative breast feeding (weeks) 28.4 (39) 26.1 (37) 24.4 (35) <0.001 
Vigorous exercise (mins/d) mean (sd) 13.4 (27) 13.9 (23) 16.6 (31) <0.001 
Total energy intake (kcal/d) mean (sd) 2362 (851) 2380 (763) 2371 (727)   0.7 
Alcohol intake (g/day) mean (sd) 9.0 (11)  8.6 (10)  8.1 (10) <0.001 
Total meat intake (g/day) mean (sd)  69.0 (78.0) 61.0 (62.3) 53.1 (57.1) <0.001 
Total fruit & veg (g/day) mean (sd) 614 (425) 630 (341) 678 (359) <0.001 
     
Dietary type n (%)    <0.001 
Mainly Meat eater  1966 (71.1) 2098 (66.1) 4395 (62.7)  
Oily Fish eater  45 (1.6) 63 (2.0) 212 (3.0)  
Other fish eater  212 (7.7) 323 (10.2) 787 (11.2)  
Vegetarian   542 (19.6) 689 (21.7) 1616 (23.1)  
Never smoked n(%) 1712 (63.0) 1889 (60.9) 4181 (61.1)  0.1 
Ex-smoker n(%) 734 (27.2) 934 (30.1) 2089 (30.6)  0.002 
Never used HRT n(%) 1955 (72.2) 2161 (69.6) 4498 (65.3) <0.001 
Never used pill n(%) 940 (34.3) 898 (28.5) 2300 (33.1)  0.9 
Socio-economic status n(%)     0.8 
Higher 1133 (41.5) 1293 (41.3) 1829 (40.9)  
Middle 1136 (41.6) 1299 (41.5) 2945 (42.6)  
Lower 463 (17.0) 540 (17.2) 1143 (16.5)  
Education level n(%)    <0.001 
No qualifications 381 (13.8) 366 (11.5) 984 (14.0)  
Non-degree qualifications 1530 (55.3) 1858 (58.6) 4120 (58.8)  
Degree 854 (30.9) 949 (29.9) 1906 (27.2)  
Family history of any cancer n(%)
4
 1030 (39.3) 1181 (39.6) 2711 (41.3)  0.06 
Family history of breast cancer n(%)
4
 208 (7.9) 228 (7.6) 537 (8.2)  0.6 
     
1
Never users: women who reported no supplement use at baseline and at second survey 
2
Past/new users: women who reported supplement use on only one questionnaire, either at baseline and at second 
survey 
3
Users at both: women who reported supplement use at both baseline and at second survey 
4
family history of cancer in first degree relatives 
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Table 3 Cancer risks for all supplement users at baseline in the UKWCS compared to non-
users (N=32665) 
Any supplement use 
at baseline 
Cases/ Unadjusted Adjusted1,2 
Non-cases HR (95% CI) HR (95% CI) 
Total cancers    
Non-users 1459/11036 1 1 
Users 2477/17693 1.06 (0.99,1.14) 1.06 (0.98,1.14)  
    
Smoking related cancers    
Non-users 146/12349         1 1 
Users 283/19887         1.22 (0.99, 1.51)    1.41 (1.10, 1.81)  
    
Colorectal cancer    
Non-users 130/12365 1 1 
Users 232/19938 1.17 (0.93, 1.46) 1.13 (0.87, 1.46) 
    
Breast cancer all women    
Non-users 502/11993 1 1 
Users 842/19328 1.03 (0.92,1.16)  1.01 (0.89,1.15)  
    
Breast cancer post-menopausal women   
Non-users 288/5927 1 1 
Users 481/10285 0.96 (0.82,1.11)  0.96 (0.81,1.13)  
    
Breast cancer pre-menopausal women   
Non-users 214/6066 1 1 
Users 361/9043 1.13 (0.94,1.35)  1.07 (0.88,1.30)  
    
1
All cancer, smoking-related cancer and colorectal cancer analyses adjusted for baseline 
covariates: age, BMI, education, hrs exercise sweating per week, alcohol intake, total energy 
intake, smoking habit, diet type 
2
Breast cancer analysis adjusted for baseline covariates: age, BMI, education, hrs exercise 
sweating per week, alcohol intake, total energy intake, diet type, parity, age at menarche, 
contraceptive pill use, HRT use 
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Table 4 Cancer risks for users at both, and for past/new users compared to never-users 
according to any supplement use at baseline and second survey in the UKWCS (N=12948) 
Any supplement use at 
baseline or second survey 
Cases/ Unadjusted Adjusted1,2 
Non-cases HR (95% CI) HR (95% CI) 
Total cancers    
Never users at both 334/2431 1 1 
Past/new users 343/2830  0.88 (0.75, 1.04)  0.96 (0.81,1.14)  
Users at both 850/6160 1.01 (0.89, 1.16)  1.01 (0.88,1.17)  
    
Smoking related cancers    
Never users at both 27/2738         1 1 
Past/new users   27/3,146         0.78 (0.44,1.37) 0.97 (0.53,1.79)  
Users at both 77/6,933         1.10 (0.70,1.75) 1.29  (0.78,2.13)  
    
Colorectal cancer    
Never users at both 35/2730 1 1 
Past/new users 27/3145 0.62 (0.36,1.07) 0.71 (0.40,1.26) 
Users at both 79/6931 0.95 (0.62,1.44) 1.00 (0.63,1.57) 
    
Breast cancer all women    
Never users at both 110/2655 1 1 
Past/new users 132/3041  1.03 (0.79, 1.34)  0.98 (0.73,1.30)  
Users at both 319/6691  1.13 (0.90,1.42)   1.08 (0.85,1.38) 
    
Breast cancer post-menopausal   
Never users at both 71/1379 1 1 
Past/new users 71/1427 0.95 (0.67,1.33)  0.90 (0.62,1.31)  
Users at both 189/3619 1.00  (0.75,1.32)  0.93 (0.68,1.26)  
    
Breast cancer pre-menopausal   
Never users at both 39/1276 1 1 
Past/new users 61/1614 1.25 (0.81,1.94)  1.17 (0.74,1.84)  
Users at both 130/3072 1.40 (0.95,2.08)  1.35 (0.91,2.01)  
    
1
All cancer, smoking-related cancer and colorectal cancer analyses adjusted for baseline covariates: age, 
BMI, education, hrs exercise sweating per week, alcohol intake, total energy intake, smoking habit, diet 
type 
2
Breast cancer analysis adjusted for baseline covariates: age, BMI, education, hrs exercise sweating per 
week, alcohol intake, total energy intake, diet type, parity, age at menarche, contraceptive pill use, HRT 
use 
 
 
 
  
